3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
2
Phase 2
1
Phase 1/2
1
Phase 1
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Esophageal Squamous Cell Carcinoma
1
Esophageal Neoplasms
1
Interventions
pembrolizumab
86
Cyclophosphamide
58
Carboplatin
57
Specimen Handling
55
fludarabine
46
Nivolumab
44
Magnetic Resonance Spectroscopy
44
Gemcitabine
41
Biopsy
40
Bevacizumab
36
Dexamethasone
32
venetoclax
31
Paclitaxel
29
Cisplatin
29
Pemetrexed
28
Injections
28
Docetaxel
26
atezolizumab
22
Ipilimumab
22
Capecitabine
22
Temozolomide
21
Rituximab
20
Oxaliplatin
20
Cetuximab
20
Azacitidine
20
Lenalidomide
19
Fulvestrant
19
abemaciclib
18
Fluorouracil
17
Vincristine
16
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Histamine H2 Antagonists
×
90 days
×
Clear all
NCT05319730
2026-05-26
MK-3475-06B
Merck Sharp & Dohme LLC
Phase 1/2
Recruiting
230 enrolled